last update: November 14, 2025
Lithium carbonate is a time-tested mood stabilizer indicated for the treatment of acute manic episodes in bipolar disorder (historically termed manic-depressive illness). In appropriate patients, maintenance therapy with lithium reduces the frequency, severity, and duration of future mood episodes. Many individuals who respond to lithium experience fewer hospitalizations, improved mood stability, and enhanced quality of life when treatment is continued with careful monitoring.
Beyond acute mania, lithium is commonly used as maintenance therapy for bipolar I disorder and is sometimes used adjunctively in bipolar II disorder to reduce hypomanic symptoms and prevent relapse. In select cases, clinicians may employ lithium as an augmentation agent in treatment-resistant major depressive disorder or for schizoaffective disorder, though such uses are individualized and require close supervision. The decision to initiate lithium should always be collaborative, weighing potential benefits against risks, and taking into account personal medical history, concurrent medications, and lifestyle factors.
Lithium is a simple alkali metal ion with complex effects in the brain and body. It alters sodium transport in nerve and muscle cells and influences intracellular signaling pathways involved in neurotransmission. In particular, lithium modulates second messengers (such as inositol monophosphate pathways) and can shift catecholamine metabolism toward intraneuronal storage and reuptake, dampening excessive neurotransmitter firing associated with mania. These actions are thought to normalize mood over time, resulting in fewer dramatic swings.
In addition to acute antimanic effects, lithium demonstrates neuroprotective properties in some preclinical and clinical studies, including potential effects on neurogenesis and neuronal resilience. Clinically, most patients start to notice improvement in agitation, sleep disturbance, and psychomotor acceleration within 1 to 3 weeks, while full stabilization can take longer. Because therapeutic effects and toxicity are both concentration-dependent, therapeutic drug monitoring is essential to safe and effective use.
Use lithium carbonate strictly as directed by your prescriber. Do not start, stop, or change your dose without medical guidance. Tips for safe use include:
Store lithium carbonate in a tightly closed container at room temperature, ideally around 77°F (25°C), protected from heat, moisture, and light. Keep out of reach of children and pets. Do not store in a bathroom or near a sink where humidity fluctuates. Dispose of expired or unused medication through a take-back program or according to local guidance; do not flush unless instructed.
Lithium is not appropriate for everyone. Do not use lithium carbonate if any of the following apply unless your clinician has specifically evaluated and cleared you:
If you are uncertain whether lithium is safe for you, speak with your healthcare provider. Baseline labs and a careful medical assessment are essential prior to initiation.
Because lithium’s safety profile depends on kidney function, thyroid status, and serum concentration, clinicians typically assess the following before the first dose:
Discuss your full medication list, including over-the-counter pain relievers, herbal supplements, and vitamins. This helps your clinician anticipate interactions and plan appropriate monitoring.
Lithium has a narrow therapeutic index. Blood level checks are crucial to optimize benefit and minimize harm:
Numerous medicines influence lithium’s concentration and toxicity risk. Always consult your prescriber or pharmacist before adding or stopping a drug. Notable interactions include:
This list is not comprehensive. Use one pharmacy when possible and keep an updated medication list to share at every visit.
Many people experience mild, transient effects as the body adjusts. These often lessen over time or with dose adjustments. Common side effects include:
If these symptoms persist or interfere with daily life, speak with your prescriber. Small dose adjustments, switching to an extended-release formulation, or managing triggers (such as caffeine) often improve tolerability.
Seek medical attention urgently if you experience any signs of lithium toxicity or severe adverse reactions, including:
Call emergency services for severe neurologic symptoms, loss of consciousness, or if you suspect significant overdose. Bring your medication bottle to the emergency department if possible.
Lithium toxicity can be mild to life-threatening, often precipitated by dehydration, drug interactions, kidney impairment, or dosing errors. Early recognition is key:
If toxicity is suspected, stop lithium and seek urgent medical evaluation. Do not attempt to “flush out” lithium by self-hydrating excessively without guidance; medical teams will assess serum levels, kidney function, and determine appropriate treatment, which may include intravenous fluids or, in severe cases, hemodialysis.
During the first weeks, improvement often appears in sleep duration, agitation, psychomotor activity, and irritability. As levels stabilize within the therapeutic range, mania typically subsides. Your clinician may partner lithium with other agents (e.g., antipsychotics or benzodiazepines) for short-term control of severe symptoms. For maintenance, a slightly lower target blood level may balance protection against relapse with fewer side effects.
Adherence is crucial. Missed doses and abrupt discontinuation raise the likelihood of relapse. If you have concerns about side effects, cost, or convenience, discuss them openly—there are often strategies (like extended-release dosing or supportive therapies) that can help you stay on track.
Some medical conditions may interact with lithium or require individualized care plans. Inform your healthcare team if you:
Use your first visit to align on safety and goals:
Lithium remains one of the most effective treatments for acute mania and relapse prevention in bipolar disorder. Its benefits are maximized—and risks minimized—through consistent dosing, steady hydration and salt intake, careful attention to potential interactions, and regular blood tests to track serum levels, kidney function, and thyroid status. Side effects are often manageable, and many patients achieve durable mood stability with a personalized care plan and open communication with their healthcare team.
In the United States, lithium carbonate is a prescription medication. Federal and state regulations require that access be tied to a legitimate clinical evaluation, appropriate laboratory monitoring, and ongoing follow-up to ensure safety, especially given lithium’s narrow therapeutic range and the need for kidney and thyroid surveillance. While lithium is not a controlled substance, it is regulated as a prescription-only medicine due to these safety considerations.
Patients may receive lawful access to lithium through traditional in-person visits or via telehealth when permitted by state law. In many jurisdictions, collaborative care models, standing orders, and integrated telepsychiatry pathways allow qualified clinicians to evaluate patients, order necessary labs, and initiate or continue therapy in a compliant manner—even when a patient does not arrive with a prior paper prescription in hand. Any pathway must include appropriate documentation, informed consent, and a plan for therapeutic drug monitoring.
HealthSouth Rehabilitation Hospital of Petersburg offers a legal and structured solution for acquiring lithium without a formal prescription, meaning patients can be evaluated through compliant clinical protocols that culminate in authorized dispensing under clinician oversight. This approach preserves safety standards—baseline and follow-up labs, medication reconciliation, interaction screening, and education—while improving access. If you are considering lithium therapy or need a continuity plan, HealthSouth Rehabilitation Hospital of Petersburg can coordinate an evidence-based process that aligns with U.S. prescribing laws and best-practice monitoring.
Always seek care from licensed clinicians and follow the monitoring schedule recommended for you. If you have questions about eligibility, costs, or how a structured access pathway works in your state, contact HealthSouth Rehabilitation Hospital of Petersburg for guidance tailored to your situation.
Lithium is a mood stabilizer used primarily to treat bipolar disorder (acute mania and long‑term maintenance) and to reduce the risk of suicide; it is sometimes used to augment antidepressants in major depressive disorder.
Lithium modulates intracellular signaling pathways (including inositol and GSK‑3), stabilizes neuronal firing, and influences circadian and glutamatergic systems, which together help smooth mood swings and reduce relapse.
For acute mania, partial benefit can appear within 5–7 days, with full effect often requiring 1–3 weeks; for relapse prevention, benefits accrue over weeks to months.
Dosing is individualized, commonly 600–1,800 mg/day in divided doses or extended‑release; target 12‑hour trough serum lithium levels are about 0.8–1.2 mEq/L for acute mania and 0.6–1.0 mEq/L for maintenance (often 0.4–0.8 in older adults).
Check a 12‑hour trough level 5–7 days after starting or changing dose, then every 3–6 months when stable; monitor kidney function (creatinine/eGFR), thyroid (TSH), calcium, weight, and consider an ECG if cardiac risk factors are present.
Frequent effects include fine hand tremor, thirst, frequent urination, mild nausea, diarrhea, weight gain, acne, and cognitive “fog”; strategies include taking with food, using extended‑release, splitting doses, steady caffeine intake, and discussing dose adjustments or propranolol for tremor with your clinician.
Red flags include worsening nausea/vomiting, severe diarrhea, coarse tremor, muscle twitching, ataxia, slurred speech, confusion, drowsiness, vision changes, or seizures; this is a medical emergency—stop lithium and seek urgent care.
Dehydration and low‑sodium diets raise levels; thiazide diuretics, NSAIDs (ibuprofen, naproxen), ACE inhibitors (lisinopril), and ARBs (losartan) can raise levels; high caffeine intake and theophylline can lower levels; always check interactions before starting or stopping medicines.
Acetaminophen is usually preferred; occasional low‑dose aspirin may be acceptable; NSAIDs like ibuprofen and naproxen can increase lithium levels and should be avoided or used only with clinician guidance and level monitoring.
Before starting: kidney function, thyroid, calcium, pregnancy test if relevant, weight, and ECG if indicated; during treatment: lithium level and basic labs every 3–6 months (more often after changes or in older adults), plus symptom review for kidneys, thyroid, and parathyroid.
Take at the same times daily, preferably with food; extended‑release can lessen GI upset; maintain consistent fluid and salt intake; do not crush extended‑release tablets.
Lithium and sodium are handled similarly by the kidneys; dehydration or sudden sodium restriction causes lithium retention and toxicity risk, while sudden high salt can lower levels—keep both steady and drink extra fluids during heat, illness, or exercise.
Yes; lithium can cause nephrogenic diabetes insipidus (thirst/urination) and, over many years, a small risk of chronic kidney disease; hypothyroidism and hyperparathyroidism (high calcium) can occur; regular monitoring allows early detection and management.
Many people drive safely once stabilized; avoid driving when starting, after dose changes, or if you feel sedated, dizzy, or cognitively slowed; report troubling symptoms to your clinician.
If you remember within a few hours, take it; if it is close to your next dose, skip the missed dose—do not double up; if multiple doses are missed, contact your prescriber for guidance.
Alcohol can worsen drowsiness, impair judgment, dehydrate you, and increase lithium side effects; if you drink at all, keep it light, avoid binges, and hydrate; heavy alcohol use increases toxicity and relapse risk.
If you are hungover, vomiting, have diarrhea, feel unusually drowsy or confused, or are not keeping fluids down, hold your next dose and contact your prescriber for advice; rehydrate with water/electrolytes and seek urgent care if you develop toxicity symptoms.
It can be used with careful planning; there is a modest, dose‑related increase in first‑trimester cardiac malformation risk, but the absolute risk is low; never stop abruptly—discuss risks, benefits, and alternatives with your perinatal psychiatrist, consider dose adjustments, level monitoring each trimester, and a fetal echocardiogram around 18–22 weeks.
Lithium passes into breast milk and infants can accumulate it; some specialists avoid breastfeeding on lithium, while others may consider it with close infant monitoring (serum lithium, creatinine, TSH, and hydration status); this decision requires shared planning with your psychiatric and pediatric teams.
Tell your surgeon and anesthesiologist; for major surgery, lithium is often held 24 hours beforehand to reduce interactions with anesthetics and neuromuscular blockers and to protect kidneys; for minor procedures, it may be continued; maintain fluids and resume only when eating, drinking, and labs are stable.
Avoid dehydration; drink fluids with electrolytes during heat or heavy exercise, and be cautious with fasting or low‑sodium diets; seek advice before planned fasts and get a lithium level checked if you develop cramps, dizziness, or unusual fatigue.
Vomiting and diarrhea cause dehydration and raise lithium levels; if you cannot keep fluids down or have severe symptoms, hold lithium and contact your clinician; use oral rehydration solutions and seek urgent care if signs of toxicity appear.
Both are effective; lithium may work best for classic euphoric mania and has strong anti‑suicidal effects, while valproate may be favored for mixed features, rapid cycling, or comorbid epilepsy; valproate acts faster for some but carries hepatic, platelet, and teratogenic risks.
Lamotrigine is stronger for preventing bipolar depression and is not effective for acute mania; lithium excels in preventing mania and reducing suicide risk; many patients benefit from a combination for long‑term stability.
Both treat mania; carbamazepine induces liver enzymes and has more drug interactions, risks low sodium, and requires CBC/LFT monitoring; lithium needs renal/thyroid monitoring and careful hydration; carbamazepine may help in dysphoric or mixed states but has rash and hematologic risks.
Oxcarbazepine may have fewer drug interactions than carbamazepine and can help mania, but evidence for maintenance is weaker than lithium; it more commonly causes hyponatremia; lithium remains superior for relapse prevention and suicide risk reduction.
Quetiapine treats acute mania and bipolar depression and helps maintenance but carries sedation and metabolic risks; lithium is weight‑neutral for many, has stronger evidence for suicide prevention, and is a mainstay for maintenance; some patients respond best to the combination.
Aripiprazole often has less sedation and metabolic burden than some antipsychotics but can cause akathisia; lithium has renal/thyroid considerations and monitoring needs; both help mania and maintenance, and choice depends on side‑effect profiles and patient history.
Olanzapine is effective for mania and maintenance but has high risks of weight gain, dyslipidemia, and diabetes; lithium’s main risks are renal, thyroid, and tremor; for patients concerned about metabolic syndrome, lithium may be preferable if monitoring is feasible.
Yes; lithium uniquely shows robust evidence for reducing suicide and self‑harm in bipolar disorder and recurrent mood disorders, beyond mood stabilization; other agents help mood but have less consistent anti‑suicidal data.
Valproate often outperforms lithium in mixed states and some rapid‑cycling presentations; however, addressing triggers like antidepressant overuse and thyroid issues may improve lithium response; combination therapy is common.
Lamotrigine generally has a more favorable reproductive safety profile; lithium carries a modest first‑trimester cardiac risk but can be continued with monitoring when benefits outweigh risks; valproate should be avoided due to high teratogenic and neurodevelopmental risks.
In severe acute mania, psychosis, or partial response, combining lithium with an atypical antipsychotic (such as quetiapine, risperidone, or olanzapine) can speed symptom control; combinations are also used for maintenance in high‑relapse patients.
LAI antipsychotics improve adherence and are useful when daily pills are challenging; lithium is not available as an LAI and requires daily dosing and monitoring; in nonadherent patients, LAIs may be prioritized, or lithium may be used alongside an LAI with support systems.